Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial

British Medical Journal

Volumn 320, Issue 7245, 2000, Pages 1297-1303

  Burge, P S ^a   Calverley, P M A ^b   Jones, P W ^c   Spencer, S ^c   Anderson, J A ^d   Maslen, T K ^d  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE; HYDROCORTISONE; PLACEBO; PREDNISOLONE; SALBUTAMOL;

ADULT; AGED; ARTICLE; CANCER; CARDIOTOXICITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL TOXICITY; HEALTH STATUS; HUMAN; HYDROCORTISONE BLOOD LEVEL; LONG TERM CARE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE;

EID: 0034643610     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.320.7245.1297     Document Type: Article

References (24)

1. 1 Thom TJ. International comparisons in COPD mortality. Am Rev Respir Dis 1989;140:27-34.
2. 2 Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997;349:1269-76.
3. 3 Murray CJL, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet 1997;349:1498-504.
4. 4 Fletcher CM, Peto R. The natural history of chronic airflow obstruction. BMJ 1978;1:1645-8.
5. 5 Jones PW, Quirk FH, Baveystock CM. The St George's respiratory questionnaire. Respir Med 1991;85(suppl B):25-31.
6. 1. JAMA 1994;272:1497-505.
7. 7 Callahan CM, Dittus RS, Katz BP. Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease. A meta-analysis, Ann Intern Med 1991;114:216-23.
8. 8 Postma DS, Peters I, Steenhuis EJ, Sluiter HJ. Moderately severe chronic airflow obstruction. Can corticosteroids slow down obstruction? Eur Respir J 1998;1:22-6.
9. 9 Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999;353:1819-23
10. 10 Pauwels RA, Lofdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB, et al. Long-term treatment with inhaled budesonide in persons with mild chronic ohstructive pulmonary disease who continue smoking. N Engl J Med 1999;340:1948-53.
11. 11 American Thoracic Society. Statement: standardization of spirometry, 1987 update. Am Rev Respir Dis 1987;136:1285-98.
12. 12 Enright PL, Johnson LR, Connett JE, Voelker H, Buist AS. Spirometry in the lung health study. I. Methods and quality control. Am Rev Respir Dis 1991;143:1215-23.
13. 13 Jone PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronir airflow limitation. The St George's respiratory questionnaire. Am Rev Respir Dis 1992;145:1321-7.
14. 14 Meecham Jones DJ, Paul EA, Jones PW, Wedzicha JA. Nasal pressure support ventilation plus oxygen compared with oxygen therapy alone in hypercapnic COPD. Am J Respir Crit Care Med 1995;152:538-44.
15. 15 Goldstein H. Multilevel statiatical models. 2nd ed. London: Edward Arnold, 1995.
16. 16 Birk AS, Raudenbush SW. Hierarchical linear models. London: Sage Publications, 1992.
17. 17 Van Elteten PH. On the combination of independent two-sample test of Wilcoxon. Bull Int Stat Inst 1960;37:351-61.
18. 18 Dompeling E, van Schayck CP, van Grunsven PM, van Herwaaden CL, Akkermans R, Molema J, et al. Slowing the deterioration of asthma and chronic obstructive pulmonary disease observed during bronchodilator therapy by adding inhaled corticosteroids. A 4-year prospective study. Ann Intern Med 1993;118:770-8.
19. 19 Jan Grunsven PM, van Schayck CP, Derenne JP, Kerstjens HA, Renkema TE, Postma DS, et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax 1999;54:7-14.
20. 20 Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Rerpir Crit Care Med 1998;157:1418-22.
21. 21 Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 1998;351:773-80.
22. 22 Jarad NA, Wedzicha JA, Burge PS, Calverley PMA for the ISOLDE study group. An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. Respir Med 1999;93:161-6.
23. 23 Osman LM, Godden DJ, Friend JAR, Legge JS, Douglas JG. Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease. Thorax 1997;52:67-71.
24. 24 Li JTC, Ford LB, Chevinsky P, Weisberg SC, Kellerman DJ, Faulkner KG, et al. Fluticasone propionate powder and lack of clinically significant effects on hypothalamic-pituitary-adrenal axis and bone mineral density over 2 years in adults with mild asthma. J Allergy Clin Immunol 1999;103:1062-8.